PYXS
Pyxis Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.89
+9.12%Year over year
Reported trailing growth
- Revenue
- +291.4%
- EBITDA
- -4.7%
- EBIT
- +13.5%
- EPS
- +10.8%
- Free cash flow
- +7.9%
- Operating cash flow
- +7.9%
Forward estimates
Based on analyst estimates
- Revenue
- +10.4%
- EBITDA
- +40.7%
- EPS
- +26.8%
Three-year CAGR
- Revenue
- -14.2%
- EBITDA
- -12.5%
- EBIT
- +5.6%
- Net income
- -3.0%
- EPS
- +3.0%
- Free cash flow
- -9.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026